Fractyl Health, Inc. Common Stock GUTS

Fractyl Health Inc is a clinical stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D). Its Revita and Rejuva candidates are designed to target root causes of metabolic diseases, allowing the company to advance metabolic disease treatment from chronic management towards prevention and reversion of the disease. The Revita DMR System (Revita), its lead product candidate, is based on its insights surrounding the potential role of the gut in obesity.

GUTS hizo una agrupación de acciones (split inverso) de 1:12 el 5 de octubre de 2026: cada 12 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• GlobeNewswire Inc. 1 oct

  Bragar Eagel & Squire, P.C. Urges Fractyl Health, Inc. Stockholders with Large Losses to Contact the Firm Before October 20th

  A class action lawsuit has been filed against Fractyl Health, Inc. for allegedly making materially false and misleading statements regarding its Revita product's effectiveness and clinical trial integrity during the period between January 13, 2025 and January 29, 2026. Investors who suffered losses are urged to contact the law firm by October 20, 2026 to participate in the action.

  

• GlobeNewswire Inc. 24 sept

  DEADLINE ALERT for FTK, AVEX, GUTS, GDDY: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

  Law Offices of Howard G. Smith has announced securities fraud class action lawsuits against four publicly-traded companies: Flotek Industries, Aevex Corp, Fractyl Health, and GoDaddy Inc. The lawsuits allege materially false and misleading statements regarding business operations and prospects. Investors have until October 2026 to file lead plaintiff motions.

  

• GlobeNewswire Inc. 24 sept

  Bronstein, Gewirtz & Grossman LLC Urges Fractyl Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

  A class action lawsuit has been filed against Fractyl Health, Inc. (NASDAQ: GUTS) alleging that company executives made materially false and misleading statements about the effectiveness of its Revita product and the integrity of REMAIN-1 clinical trial results. Investors who purchased Fractyl securities between January 13, 2025 and January 29, 2026 may be eligible to join the lawsuit, with a lead plaintiff deadline of October 20, 2026.

  

• GlobeNewswire Inc. 23 sept

  Robbins LLP Urges GUTS Stockholders to Contact the Firm for Information About the Class Action Against Fractyl Health, Inc.

  Robbins LLP announced a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) for allegedly misleading investors about the efficacy of its Revita DMR System. The company's stock plummeted 68% on January 29, 2026, after disclosing disappointing six-month clinical trial data that fell short of investor expectations. The lawsuit covers investors who purchased securities between January 13, 2025 and January 29, 2026.

  

• GlobeNewswire Inc. 22 sept

  Pomerantz Law Firm Announces the Filing of a Class Action Against Fractyl Health, Inc. and Certain Officers – GUTS

  Pomerantz LLP filed a class action lawsuit against Fractyl Health, Inc. (NASDAQ: GUTS) for alleged securities fraud. The lawsuit claims defendants made materially false statements about the efficacy of Revita, their diabetes and obesity treatment device. On January 29, 2026, Fractyl disclosed disappointing six-month data from the REMAIN-1 Midpoint Cohort showing only 4.5% weight regain versus 7.5% in the sham arm, and revealed operational issues at one clinical site. The stock price fell 68.03% following the disclosure. The class period covers purchases between January 13, 2025 and January 29, 2026.